Every year, nearly half a million Americans are diagnosed with Lyme disease, and most recover fully after a standard course of antibiotics. But for a subset of patients, fatigue, joint pain, and brain fog linger for months or years, raising a question that has divided infectious disease researchers for decades: Could the bacterium behind Lyme disease survive treatment?
A series of peer-reviewed studies, from tightly controlled animal experiments to rare analyses of human tissue, now shows that fragments of Borrelia burgdorferi, the spiral-shaped bacterium transmitted by blacklegged ticks, can be detected in the body long after antibiotics are finished. Whether those fragments represent living organisms or harmless debris remains one of the most contested questions in tick-borne disease research, and as of spring 2026, no definitive human study has settled the debate.
What the human evidence actually shows
The most rigorous direct test in humans came from a prospective study led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The team used a technique called xenodiagnosis: laboratory-raised larval blacklegged ticks were placed on the skin of treated Lyme patients to see whether the ticks could pick up live Borrelia. The study, published in Clinical Infectious Diseases, enrolled patients who had been treated after an initial erythema migrans rash as well as patients with persistent symptoms following standard therapy.
The result was largely reassuring. Xenodiagnosis found no recoverable organisms in the vast majority of participants, regardless of whether they still had symptoms. A small number of equivocal signals left room for debate about borderline cases, but the study did not demonstrate clear evidence of ongoing, culturable infection after recommended antibiotic courses. The trial protocol on ClinicalTrials.gov documents the design, including tick-feeding procedures, follow-up intervals, and laboratory methods.
On the other end of the spectrum sits a single but striking autopsy report. Published by Middelveen and colleagues in the journal Healthcare, the paper examined the tissues of a patient who had undergone extensive antibiotic treatment over a prolonged illness and found Borrelia burgdorferi antigens and DNA in multiple organs. The analysis drew on histology, immunohistochemistry, confocal microscopy, fluorescence in situ hybridization, PCR, and metagenomic sequencing. It remains one of the only papers to directly document bacterial material in human organs after treatment, though it represents a single case and cannot tell us how common such findings might be or whether the material was causing symptoms.
Those two data points, one from a controlled cohort and one from an autopsy, are essentially the entire direct human evidence base on persistence. They point in different directions, and nothing published since has resolved the tension between them.
Animal studies paint a more persistent picture
Where the human data is thin, animal research is considerably more detailed. In a widely cited 2012 study published in PLOS ONE, Monica Embers and colleagues at the Tulane National Primate Research Center infected rhesus macaques with disseminated Borrelia burgdorferi, treated them with antibiotics, and then searched their tissues using PCR, RT-PCR, xenodiagnosis, and direct tissue analysis. Bacterial DNA was found in multiple organs months after therapy, even when standard culture methods came back negative.
Mouse studies reinforced those findings across different bacterial strains and genetic backgrounds. In controlled experiments, post-antibiotic Borrelia persisted in a non-cultivable state, with resurgence signals detected through PCR-based tissue testing and xenodiagnostic ticks. A separate study published in Antimicrobial Agents and Chemotherapy tracked two strains, N40 and B31, in both genetically susceptible and resistant mice over roughly 12 to 18 months after treatment. Low-level DNA signals waxed and waned over time, establishing that persistence was not limited to a single strain or host genotype.
Taken together, the animal work is peer-reviewed, replicated across species and strains, and consistent: Borrelia material can survive antibiotic treatment under laboratory conditions. What the animal work cannot do is tell us how often this happens in humans, or whether it matters clinically when it does.
The gap between detection and disease
At the heart of the scientific dispute is a deceptively simple question: Does finding bacterial DNA mean the bacteria are still alive?
PCR and related molecular tools can detect vanishingly small fragments of genetic material, but they cannot distinguish between a living, replicating organism and inert debris that the immune system has not yet cleared. In the animal models, culture methods often fail even when DNA is present. That could mean the bacteria have shifted into a dormant, non-cultivable form, or it could mean the DNA is left over from organisms the antibiotics already killed.
The human xenodiagnosis trial found no evidence of viable, transmissible bacteria in most treated patients, which sits uneasily alongside the animal data showing persistent signals in controlled infections. Whether the difference reflects genuine biological variation between species, differences in immune responses, gaps in detection sensitivity, or the messy reality of natural human infection compared to standardized laboratory models is not yet clear.
Federal health agencies have drawn careful lines around this ambiguity. The CDC distinguishes Post-Treatment Lyme Disease Syndrome (PTLDS) from the contested term “chronic Lyme disease” and states that the cause of prolonged symptoms is currently unknown and not established as ongoing infection. NIAID similarly acknowledges the animal-model evidence but separates PTLDS from unproven claims about chronic active infection that are sometimes used to justify long-term antibiotic regimens outside guideline-based care.
A recent analysis in the CDC’s Emerging Infectious Diseases journal examined nonspecific persistent symptoms in high-incidence U.S. areas from 2017 through 2021 and framed PTLDS-like symptom clusters within the broader category of post-infectious syndromes. That framing matters because it suggests the lingering symptoms some Lyme patients experience may share mechanisms with conditions seen after other bacterial and viral illnesses, including immune dysregulation, autonomic dysfunction, and persistent inflammatory changes, rather than being uniquely driven by surviving bacteria.
What this means for patients right now
For the roughly 10 to 20 percent of treated Lyme patients who develop prolonged symptoms, the ambiguity in the research has real consequences. The existing literature does not support routine use of extended or repeated antibiotic courses beyond what guidelines recommend. Multiple randomized controlled trials have failed to show sustained benefit from prolonged antibiotics for PTLDS, and the risks, including Clostridioides difficile infection, intravenous line complications, and antimicrobial resistance, are well documented.
At the same time, the recognition of PTLDS and its overlap with other post-infectious syndromes underscores that these symptoms are real and deserve clinical attention. Current best practice focuses on symptom management: pain treatment, physical rehabilitation, cognitive support, and, when appropriate, mental health care.
Why the translational gap between animal models and human disease remains open
No large-scale longitudinal human study has yet tracked treated Lyme patients using advanced detection methods such as metagenomics, RNA sequencing, or serial xenodiagnosis over multiple years. Researchers studying the macaque and mouse models have not definitively shown how their findings translate to human disease mechanisms. The animal evidence is robust and replicated, but the leap from a controlled laboratory infection in a rhesus macaque to the heterogeneous course of natural human Lyme disease involves differences in immune architecture, treatment timing, bacterial load, and tissue tropism that no existing study has fully bridged.
Until that translational gap is closed, the honest summary of the science as of spring 2026 is this: Borrelia burgdorferi material can persist after antibiotics in animals, and possibly in some humans. Whether that persistence drives ongoing symptoms, or is simply a biological footnote the immune system will eventually erase, is a question the field has not yet answered. Clinicians and patients are left navigating between incomplete human evidence and more robust but imperfectly translatable animal data, with federal guidance emphasizing supportive care over unproven attempts to eradicate a hypothetical persistent infection.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
